Manuel Monreal: DOACs Show Advantages Over VKAs in DVT Patients
Manuel Monreal, Coordinator of the RIETE Registry, shared a post on X about a recent article he and his colleagues co-authored, published in The European Journal of Internal Medicine, adding:
“Among DVT patients with similar eligibility for the pivotal RCTs, DOACs were associated with lower risks of recurrent VTE and major bleeding.
But no significant reduction was observed in trial-ineligible patients (around 15 percent of the total).”
Title: Recurrent venous thromboembolism and bleeding during anticoagulation in patients with deep-vein thrombosis treated with vitamin K antagonists or direct oral anticoagulants: insights from the RIETE registry
Authors: Paolo Prandoni, Raffaele Pesavento, Franca Bilora, Benjamin Brenner, Iria Francisco, Germán Sierra-Palomares, Ángeles Fidalgo, Jana Hirmerova, Samuel Fonseca, Manuel Monreal
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP